Pathway Financial Advisers LLC Buys 5,526 Shares of Kenvue Inc. (NYSE:KVUE)

Pathway Financial Advisers LLC raised its stake in shares of Kenvue Inc. (NYSE:KVUE) by 107.7% during the 3rd quarter, according to the company in its most recent filing with the SEC. The firm owned 10,657 shares of the company’s stock after purchasing an additional 5,526 shares during the quarter. Pathway Financial Advisers LLC’s holdings in Kenvue were worth $247,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Vanguard Group Inc. increased its holdings in shares of Kenvue by 12.0% during the 1st quarter. Vanguard Group Inc. now owns 166,789,085 shares of the company’s stock worth $3,579,294,000 after purchasing an additional 17,908,497 shares during the period. Price T Rowe Associates Inc. MD increased its holdings in shares of Kenvue by 23.1% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 134,565,333 shares of the company’s stock worth $2,887,773,000 after purchasing an additional 25,238,112 shares during the period. Massachusetts Financial Services Co. MA increased its holdings in shares of Kenvue by 9.6% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 79,863,967 shares of the company’s stock worth $1,451,927,000 after purchasing an additional 7,023,047 shares during the period. JPMorgan Chase & Co. increased its holdings in shares of Kenvue by 11.1% during the 1st quarter. JPMorgan Chase & Co. now owns 68,319,998 shares of the company’s stock worth $1,466,147,000 after purchasing an additional 6,825,611 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Kenvue by 21.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 43,444,085 shares of the company’s stock valued at $789,813,000 after acquiring an additional 7,546,362 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Citigroup decreased their target price on shares of Kenvue from $21.00 to $20.00 and set a “neutral” rating on the stock in a research report on Wednesday, July 10th. Bank of America lifted their target price on shares of Kenvue from $24.00 to $27.00 and gave the company a “buy” rating in a research report on Tuesday, October 22nd. UBS Group lifted their target price on shares of Kenvue from $20.00 to $22.00 and gave the company a “neutral” rating in a research report on Wednesday, August 7th. JPMorgan Chase & Co. lifted their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. Finally, Deutsche Bank Aktiengesellschaft lifted their target price on shares of Kenvue from $23.00 to $24.00 and gave the company a “buy” rating in a research report on Wednesday, August 7th. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have given a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $22.64.

Kenvue Price Performance

NYSE:KVUE opened at $22.90 on Thursday. The firm has a market cap of $43.85 billion, a PE ratio of 29.36, a price-to-earnings-growth ratio of 3.00 and a beta of 1.40. Kenvue Inc. has a 12 month low of $17.67 and a 12 month high of $23.55. The company has a quick ratio of 0.68, a current ratio of 0.99 and a debt-to-equity ratio of 0.69. The company’s 50-day moving average price is $22.48 and its two-hundred day moving average price is $20.36.

Kenvue (NYSE:KVUE) last announced its earnings results on Tuesday, August 6th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.04. Kenvue had a net margin of 7.23% and a return on equity of 21.80%. The company had revenue of $4 billion for the quarter, compared to analyst estimates of $3.93 billion. During the same period in the prior year, the business earned $0.32 earnings per share. Kenvue’s quarterly revenue was down .3% on a year-over-year basis. On average, equities analysts anticipate that Kenvue Inc. will post 1.08 EPS for the current fiscal year.

Kenvue Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a dividend of $0.205 per share. The ex-dividend date of this dividend is Wednesday, November 13th. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.58%. Kenvue’s payout ratio is 105.13%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.